To assess the in vivo impact of Fas/FasL activation in E2f2−/− mice, animals were treated with concanavalin A (ConA), as shown in Figure 6A, a widely-used model for hepatitis in mice, with important similarities to immune-mediated hepatitis in humans [27]. Here, FASLG is linked to hepatitis A virus infection.